@inproceedings{inproceedings, title = {{DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer}}, url = {{}}, year = {{2020}}, month = {{1}}, author = {{Niazi T and Williams S and Davis ID and Stockler MR and Martin AJ and Hague W and Bracken K and Gorzeman M and Roncolato F and Yip S and Horvath L et al}}, volume = {{38}}, journal = {{JOURNAL OF CLINICAL ONCOLOGY}}, issue = {{6}}, note = {{Accessed on 2025/09/21}}}